Leadership shake-up at Longeveron (NASDAQ: LGVN) as CEO exits, interim chief named

Rhea-AI Filing Summary

Longeveron Inc. reported a leadership change. On August 27, 2025, Chief Executive Officer Wa’el Hashad stepped down as CEO and as a member of the Board of Directors to pursue other opportunities. The Board appointed Than Powell, currently Chief Business Officer and head of business development, to serve as interim Chief Executive Officer effective September 4, 2025, until a permanent successor is identified.

The Board also named company founder and Chief Science Officer Dr. Joshua Hare as Executive Chairman. As interim CEO, Mr. Powell will receive a base salary of $500,000, a potential prorated target bonus equal to 60% of base salary, and an equity grant of restricted stock units and stock options, subject to vesting. The company states there are no arrangements or related‑party transactions influencing Mr. Powell’s selection for this role.

Insights

Corporate governance and biotech sector analyst

Longeveron announces an immediate CEO change and interim leadership structure.

Longeveron is undergoing a notable governance transition as CEO Wa’el Hashad steps down from both the chief executive role and the Board. The Board has appointed existing executive Than Powell as interim CEO effective September 4, 2025, while founder and Chief Science Officer Dr. Joshua Hare moves into the Executive Chairman role. This keeps leadership within insiders who know the business well.

Mr. Powell’s background includes more than 25 years in pharmaceutical and biotech leadership and prior roles at GSK, Eli Lilly, Surescripts, and a venture-backed health technology company. His interim CEO compensation package includes a $500,000 base salary, a target bonus set at 60% of base salary (prorated), and equity incentives via restricted stock units and stock options, aligning pay partly with equity performance.

The company notes there are no special arrangements or related-party transactions tied to Mr. Powell’s appointment, which supports standard governance practices. The combination of an interim CEO and an Executive Chairman structure may concentrate strategic and scientific oversight with the founder while the Board searches for a permanent chief executive, with future disclosures expected to clarify the long-term leadership plan.

false 0001721484 0001721484 2025-08-27 2025-08-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 27, 2025

Longeveron Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40060		47-2174146
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1951 NW 7^th Avenue, Suite 520, Miami, Florida 33136

(Address of principal executive offices)

Registrant’s telephone number, including area code: (305) 909-0840

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.001 par value per share		LGVN		NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 27, 2025, Longeveron Inc. (the “Company”) and Wa’el Hashad, Chief Executive Officer, determined that Mr. Hashad would step down from his role as Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), effective immediately, so as to allow Mr. Hashad to pursue other opportunities. In connection with Mr. Hashad’s departure, the Board has appointed Than Powell, the Company’s current Chief Business Officer and head of business development, to serve as interim Chief Executive Officer, effective September 4, 2025, and until such time as a permanent successor has been identified.

Further, the Board has appointed Dr. Joshua Hare, the Company’s founder, Chief Science Officer and current Board Chair, as Executive Chairman of the Board.

Mr. Powell, age 47, has over 25 years of pharmaceutical and biotech leadership across multiple industry-leading organizations, including GSK and Eli Lilly. Prior to Longeveron, Mr. Powell led Corporate Development & Strategy for Surescripts, ultimately resulting in the company’s acquisition by TPG. Before that role, Mr. Powell was founder and CEO of Epulate, a venture-backed health technology company focused on Transplant Immunology. Mr. Powell holds a Bachelor of Arts in Economics from DePauw University and a Master of Business Administration from Stanford University, Graduate School of Business. In the role of interim Chief Executive Officer, Mr. Powell will be entitled to receive a base salary of $500,000, potential prorated target bonus payments at 60% of base salary, and an equity grant consisting of restricted stock units and stock options, subject to vesting.

There are no arrangements or understandings between Mr. Powell and any other person pursuant to which he was selected as an officer. Mr. Powell has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

9.01 Financial Statements and Exhibits  

(d) Exhibits.

The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.

Exhibit No.		Description
99.1		Press Release dated September 3, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LONGEVERON INC.
Date: September 3, 2025	/s/ Lisa Locklear
	Name:	Lisa Locklear
	Title:	Chief Financial Officer

2

FAQ

Why did Longeveron (LGVN) file this 8-K?

Longeveron Inc. filed this 8-K to disclose that Chief Executive Officer Wa’el Hashad has stepped down from his roles as CEO and Board member, and to announce new leadership appointments, including an interim CEO and an Executive Chairman.

Who is the new interim CEO of Longeveron (LGVN)?

Than Powell, previously Longeveron’s Chief Business Officer and head of business development, has been appointed interim Chief Executive Officer effective September 4, 2025, and will serve until a permanent successor is identified.

What role will Longeveron founder Dr. Joshua Hare now hold?

Longeveron’s founder and Chief Science Officer, Dr. Joshua Hare, has been appointed Executive Chairman of the Board, expanding his leadership responsibilities while continuing to serve on the Board.

What compensation will Longeveron’s interim CEO receive?

As interim CEO, Than Powell will receive a base salary of $500,000, a potential prorated target bonus equal to 60% of base salary, and an equity grant of restricted stock units and stock options, subject to vesting.

Are there any special arrangements behind Than Powell’s appointment at Longeveron (LGVN)?

The company states there are no arrangements or understandings between Than Powell and any other person pursuant to which he was selected as an officer, and that he has no material interest in related-party transactions requiring disclosure.

Why did Longeveron’s CEO Wa’el Hashad step down?

Longeveron reports that Wa’el Hashad stepped down from his role as Chief Executive Officer and Board member on August 27, 2025 so he can pursue other opportunities.